We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Suboptimal Weight Affects Survival in Cervical Cancer

By HospiMedica International staff writers
Posted on 05 May 2016
Both overweight and underweight women with cervical cancer did not live as long as their normal-weight counterparts, according to a new study.

Researchers at the University of Cincinnati (OH, USA) and the University of North Carolina (UNC; Chapel Hill, USA) conducted a retrospective cohort study of 623 women with cervical cancer treated from July 2000 to March 2013, classifying the women according to their body mass index (BMI). More...
In all, 4% of the women were underweight, 30% were normal weight, and 66% were overweight or obese. The primary outcome was overall survival; secondary outcomes included stage, histopathology, disease-specific survival (DSS), and recurrence free survival (RFS).

The results showed that the median overall survival time in overweight or obese women was six months shorter than in women of normal weight (22 versus 28 months); for underweight women, median overall survival time was cut in half (14 versus 28 months). There was no difference in age, stage at presentation, grade, or histology between weight categories. After controlling for prognostic factors, underweight and overweight/obese patients had worse median RFS than normal weight patients. The study was published on April 14, 2016, in in Gynecologic Oncology.

“In understanding the effect of BMI on cervical cancer outcomes, it is important to recognize that both extremes of weight appear to negatively impact survival. A potential unifying hypothesis connecting both extremes of weight to poor cancer prognosis is chronic systemic inflammation,” wrote lead author Leslie Clark, MD, of UNC, and colleagues. “Both patients with cancer cachexia/sarcopenia and overweight/obese patients are in a heightened inflammatory state, which may lead to increased cell proliferation and inhibition of apoptosis.”

"However, this is likely not the only mechanism of poor outcomes. Co-morbid medical conditions might account for some of the differences in survival, particularly in morbidly obese patients,” concluded the authors. “Providers should optimize weight in underweight and overweight/obese patients to attempt to improve outcomes in these women. Interventions that target nutritional counseling and physical activity should be explored in these populations.”

Related Links:
University of Cincinnati
University of North Carolina

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
Gold Member
Blood Gas Analyzer
i-Check200
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Medical Imaging

view channel
Image: Visual Abstract (Andrea Farolfi et al., Journal of Nuclear Medicine, 2026. DOI: 10.2967/jnumed.126.272108)

PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer After Nondiagnostic MRI

Prostate cancer can be difficult to detect when magnetic resonance imaging (MRI) findings are negative or inconclusive. Men with persistent clinical risk factors may still require biopsy, yet standard... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: WHX returns to Dubai Exhibition Centre, Expo City, and Dubai World Trade Centre from 5–28 January 2027 (Photo courtesy of World Health Expo)

World Health Expo to Showcase Trillion-Dollar Growth Across Pharma, Biotech, Longevity and Wellness at 2027 Edition

World Health Expo (WHX) expands with the new Pharma, Biotech, Longevity and Wellness industry sectors More than 235,000 professional visits, over 4,200 exhibitors and representatives from over... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.